AGIO AGIOS PHARMACEUTICALS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Commercial-stage biopharma focused on rare hematology diseases via PK activator small molecules
• • New regulatory approvals for mitapivat: FDA approval of AQVESME™ for thalassemia anemia (Dec 2025), Saudi Arabia approval for PYRUKYND®, EMA positive opinion pending final decision early 2026
• • Strategic shift: Divested oncology business in 2021, monetized vorasidenib milestone and royalty rights for total $1.1B cash inflow by 2024
• • R&D investment milestone: $10M milestone payment to Alnylam in 2025 under license for siRNA candidate AG-236 in polycythemia vera
• • Noteworthy metric: Completed phase 3 SCD trial with mitapivat, 40.6% hemoglobin response vs 2.9% placebo, launched U.S. commercial thalassemia product in Jan 2026

Risk Factors

• • Regulatory risk: FDA REMS requirements for AQVESME™ due to boxed warning on hepatocellular injury risk
• • Macroeconomic risk: geopolitical events like war impacting patient enrollment and clinical trial site operations internationally
• • Supply chain risk: reliance on third-party CROs and contractors with limited control over compliance and timelines
• • Market disruption risk: competition for patient enrollment from other companies’ clinical trials in same indications
• • Financial risk: $130M potential milestone and royalty payments under license agreement with Alnylam for siRNA candidate targeting TMPRSS6

Management Discussion & Analysis

• • Revenue from PYRUKYND® and AQVESME™ product sales began in 2022 and 2026 respectively; milestone income $200M in 2024 from Vorasidenib FDA approval
• • Net income $673.7M in 2024 driven by $1.09B total gain from Vorasidenib royalty rights sale and milestone payment, net loss $412.8M in 2025, net loss $352.1M in 2023
• • Best segment: Oncology contingent payments, $889.1M gain in 2024 from contingent payments sale; Worst segment: ongoing R&D and commercialization expenses driving net losses in 2025
• • Cash inflows include $905M from sale of Vorasidenib Royalty Rights in 2024; R&D expenses include $17.5M upfront license payment plus $10M milestone payment to Alnylam in 2025
• • Future outlook: FDA pre-sNDA meeting Q1 2026 for mitapivat in sickle cell disease; EU approval expected early 2026; continued investment in clinical trials and commercialization expansion

What are the latest AGIO SEC filings in 2026?

AGIOS PHARMACEUTICALS, INC. (AGIO) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on April 29, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AGIO file its most recent 10-K annual report?

AGIOS PHARMACEUTICALS, INC. (AGIO) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AGIO 10-Q quarterly reports?

AGIOS PHARMACEUTICALS, INC. (AGIO)'s most recent 10-Q quarterly report was filed on April 29, 2026. SignalX displays every AGIO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AGIO filed recently?

AGIOS PHARMACEUTICALS, INC. (AGIO)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AGIO insider trading activity (Form 4)?

SignalX aggregates every AGIO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AGIO file with the SEC?

AGIOS PHARMACEUTICALS, INC. (AGIO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AGIO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AGIOS PHARMACEUTICALS, INC. (AGIO).

What is AGIO's SEC CIK number?

AGIOS PHARMACEUTICALS, INC. (AGIO)'s SEC CIK (Central Index Key) number is 1439222. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1439222 to look up all AGIO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AGIO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from AGIOS PHARMACEUTICALS, INC. (AGIO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.